Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Alterity Therapeutics Limited (ATHE) provides access to the company’s disclosures as a foreign private issuer listed on NASDAQ. Alterity files reports under the Securities Exchange Act of 1934, including its annual report on Form 20‑F and current reports on Form 6‑K, and describes itself in these documents as a development stage enterprise focused on neurodegenerative diseases.
For investors following this clinical stage biotechnology company, Form 6‑K filings are particularly important. They often include material that has been released to the Australian Securities Exchange, such as quarterly Appendix 4C cash flow reports, clinical trial updates for ATH434 in Multiple System Atrophy (MSA), regulatory designations like U.S. FDA Fast Track status, and information on capital raisings or strategic placements. Other 6‑K submissions may contain meeting results, presentations to shareholders, and notices related to board or director changes.
Alterity’s Form 20‑F annual report (when filed) typically consolidates information on its business overview, risk factors, research and development focus on Parkinsonian and other neurodegenerative disorders, and its status as a clinical stage company. These filings complement the company’s scientific and clinical communications by outlining its segment focus on research and development and its listing arrangements on the Australian Securities Exchange and NASDAQ.
On Stock Titan, this page surfaces Alterity’s SEC filings as they are made available from EDGAR and pairs them with AI‑powered summaries to help readers interpret technical language. Users can quickly see the purpose of each 6‑K or 20‑F, identify items related to ATH434 clinical data, regulatory interactions, cash flow disclosures, and corporate governance, and then drill into the full text for detailed review.
Alterity Therapeutics reported positive regulatory progress for its lead drug ATH434 in Multiple System Atrophy (MSA). After a Type C Meeting, the FDA provided written feedback supporting the company’s clinical pharmacology and non-clinical plans for a planned Phase 3 pivotal trial.
The company now aims to secure FDA agreement on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design, with an End-of-Phase 2 meeting targeted for mid-year 2026. ATH434 has already shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and additional positive data in an open-label Phase 2 study in advanced MSA, and Alterity is preparing to initiate Phase 3.
Alterity Therapeutics Limited has reported a proposed issue of 150,000,000 options as payment for services to Lawrence Gozlan and Chairman Julian Babarczy. The options have an exercise price of A$0.02 and expire five years after issue, with an expected expiry date of 26/6/2031.
The options are to be issued for non-cash consideration, with each option exercisable into one fully paid ordinary share. The proposed issue date is 26/6/2026 and is subject to shareholder approval at a meeting scheduled for 27/5/2026 under ASX Listing Rule 7.1.
Alterity Therapeutics Limited is introducing an opt-out unmarketable parcel sale facility for shareholders holding less than A$500 in fully paid ordinary shares. Using the 9 March 2026 closing price of $0.008, this equates to holdings of fewer than 62,500 shares.
About 5,868 shareholders are on the register, of which approximately 59.2% hold an unmarketable parcel. These shareholders can either do nothing and have their shares sold without brokerage, or retain their holding by returning a Share Retention Form or increasing their holding to at least 62,500 shares by 7.00pm (AEST) on 24 April 2026.
Alterity Therapeutics Limited has filed a Form 6-K highlighting its planned participation in the Bell Potter Healthcare Horizons Summit in Sorrento, Australia on 12-13 March 2026. CEO David Stamler, M.D. will join a fireside chat on optimising late-stage clinical trials and hold 1-on-1 investor meetings.
The company is a clinical-stage biotechnology business developing disease-modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders. Its lead candidate, ATH434, has shown clinically meaningful efficacy in a Phase 2 trial and positive results in an open-label Phase 2 study, and the company is preparing a Phase 3 pivotal trial in MSA.
Alterity Therapeutics filed a Form 6-K to disclose the appointment of Daniel O. Claassen, M.D., M.S. as Chief Medical Advisor beginning in March 2026. Dr. Claassen is a tenured professor of neurology at Vanderbilt University Medical Center and an internationally recognized expert in neurodegenerative diseases, especially movement disorders and multiple system atrophy (MSA).
He previously served as coordinating investigator for Alterity’s Phase 2 study of its lead drug candidate ATH434 in MSA and has led numerous clinical trials across academia and industry. Alterity highlights that ATH434 showed clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open-label Phase 2 study in advanced MSA, and notes it is preparing a Phase 3 pivotal trial.
Alterity Therapeutics reported a larger loss for the half-year ended 31 December 2025 as it advanced its lead drug ATH434 toward late-stage development. Revenue from ordinary activities was A$909,750, up 717%, mainly from higher interest income, while a R&D tax incentive contributed A$2,803,428 in other income.
The net loss after tax attributable to members widened 34% to A$9,615,849, driven by increased research and development expenses of A$7,842,289 and general and administration costs of A$5,116,261, including A$2,215,164 of share-based payments. Basic and diluted loss per share improved to 0.09 cents from 0.14 cents as the share count rose.
Alterity strengthened its balance sheet, raising approximately A$20 million in September 2025 and ending the period with cash and cash equivalents of A$49,200,547. Net tangible asset backing increased to 0.50 cents per share from 0.14 cents, and total equity rose to A$54,267,999. Operationally, the company highlighted positive Phase 2 data for ATH434 in Multiple System Atrophy, ongoing scientific engagement, and preparations for an End-of-Phase-2 FDA meeting targeted for mid-2026.
Alterity Therapeutics Limited reports its Q2 FY26 cash flow and a corporate update centered on lead candidate ATH434 for Multiple System Atrophy (MSA). The company highlights strengthened Phase 2 data, a Fast Track designation from the U.S. FDA, and active planning for an End-of-Phase 2 meeting targeted for mid-2026 to shape a pivotal Phase 3 trial.
New analyses of Phase 2 data showed an improved efficacy signal for the 75 mg dose on a modified UMSARS Part I endpoint and a beneficial effect on orthostatic hypotension symptoms. Alterity also points to a potential commercial opportunity of US$2.4 billion for ATH434 in MSA and is advancing partnering discussions with multiple pharmaceutical companies.
As of 31 December 2025, Alterity held A$49.2 million in cash and cash equivalents, with quarterly operating cash outflows of A$5.28 million, implying an estimated 9.3 quarters of funding. The company strengthened governance with a new Chair, added board representation for the CEO, and expanded its leadership team to support late-stage development and strategic partnering.
Alterity Therapeutics provides a shareholder update highlighting major progress with its lead drug candidate ATH434 for Multiple System Atrophy (MSA) and outlining priorities for 2026. In 2025 the company completed its Phase 2 program in MSA, reporting “resoundingly favourable” results, with ATH434 shown to be safe and well-tolerated and to provide strong signals of efficacy, including slowing disease progression and improving mobility and orthostatic hypotension, with no drug-related serious or severe adverse events compared with placebo. Alterity is now planning a pivotal Phase 3 program in MSA and expects to hold an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize the Phase 3 trial design. The company also reports governance and leadership enhancements, including appointing Julian Babarczy as Chair of the Board and expanding its management team in investor relations and corporate strategy to support potential future commercialization and increased business development.